gray glp-1 weight loss drug study finds small increase in risk of osteoporosis and gout GLP-1 medications mimic the effects

For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission

Contribution statement All authors contributed to the conception and design of this review, drafting of the article, revising for critically important content and approved the final version to be published

The trouble is that the number of people who lost enough weight and kept it off was so small

Still, results should be carefully generalized to cases of background kidney dysfunction or when using drugs with narrow therapeutic index

Compounded semaglutide and tirzepatide are well-established GLP-1 receptor agonists with substantial clinical evidence supporting weight loss

Liu W, Luo Z, Zhou J et al